Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | CPB1 | P15086 | 7/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL21047047 | 1.00 | KDM2B (0.44) | KDM2BKDM4CUSP30CPB1CPB2 | |
| Formic Acid SCHEMBL21047073 | 1.00 | KDM2B (0.44) | KDM2BKDM4CUSP30CPB1CPB2 | |
| Formic Acid SCHEMBL21047069 | 1.00 | KDM2B (0.44) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL20472296 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL19859531 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL19859519 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL19859517 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL20472297 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL19859522 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 | |
| SCHEMBL19859528 | 0.96 | KDM2B (0.47) | KDM2BKDM4CUSP30CPB1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | KDM2B 2055/4885KDM4C 1827/4885USP30 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.